IDEXX Laboratories Stock Price, News & Analysis

IDEXX Laboratories (Nasdaq: IDXX), a leading pet healthcare innovator, has released its 2024 Corporate Responsibility Report highlighting significant achievements across three key pillars. The company launched groundbreaking innovations including the IDEXX inVue Dx™ Cellular Analyzer and IDEXX Cancer Dx™ testing for early cancer detection in pets.

Notable accomplishments include supporting over 79,000 animals in underserved communities, providing $5.5 million in continuing education credits, and achieving an 80% employee engagement rate. Environmental initiatives featured signing three virtual power purchase agreements and maintaining a 35% electric and hybrid commercial fleet. The company serviced over 34,000 instruments and completed 90,000 point-of-service upgrades to advance product circularity.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced the appointment of Joseph L. (Jay) Hooley to its Board of Directors, effective July 10, 2025. Hooley, the former Chair and CEO of State Street Corporation, brings extensive strategic and financial leadership experience to IDEXX.

Hooley currently serves as lead independent director at Exxon Mobil Corporation and is on the board of Aptiv PLC. With his addition, the IDEXX Board now consists of ten directors, with nine being independent. His appointment strengthens the board's expertise in corporate governance and global business operations.

IDEXX Laboratories (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced key upcoming investor events. The company will release its Q2 2025 financial results on Monday, August 4, 2025, before market open, followed by an analyst conference call at 8:30 a.m. EDT.

Additionally, IDEXX will host its 2025 Investor Day on Thursday, August 14, 2025, from 8:00 am to 12:00 pm EDT at its Westbrook, Maine headquarters. The event will be accessible via webcast, with in-person attendance available for institutional investors and analysts through advance registration.

IDEXX Laboratories (NASDAQ: IDXX) has launched the Catalyst Cortisol Test, marking the third expansion of its Catalyst platform in under a year. This innovative test measures real-time cortisol concentrations in dogs to aid in diagnosing Addison's disease and Cushing's syndrome. The test provides point-of-care diagnostic capabilities with accuracy comparable to IDEXX Reference Laboratories. Key features include interpretive guidance through integration with IDEXX Vetlab Station and VetConnect PLUS, and an efficient load-and-go workflow. The test will launch in the U.S. and Canada by July 2025, followed by a global rollout to over 75,000 Catalyst chemistry analyzers starting Q3 2025. This development enhances veterinarians' ability to diagnose and treat life-threatening endocrine disorders during patient visits, particularly benefiting cases of Addison's disease, which is notoriously difficult to diagnose, and Cushing's syndrome, which requires long-term management.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced two upcoming investor events. The company's executives Andrew Emerson (CFO) and Tina Hunt (EVP, Global Strategy and Commercial) will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 28, 2025, from 10:55 am to 11:25 am EDT.

Additionally, IDEXX will host its 2025 Investor Day on August 14, 2025, at its corporate headquarters in Westbrook, Maine. The event will run from approximately 8:00 am to 12:00 pm EDT. Both events will be accessible via live webcast through the company's investor relations website. Institutional investors and analysts interested in attending the Investor Day in person must register by contacting investorrelations@idexx.com.

IDEXX Laboratories (NASDAQ: IDXX) reported Q1 2025 results with revenue of $998 million, showing 4% reported and 5% organic growth. The company's EPS reached $2.96, up 5% reported and 7% on a comparable basis. Key highlights include CAG Diagnostics recurring revenue growth of 3% reported and 4.5% organic, supported by strong IDEXX VetLab consumables performance and over 300 IDEXX inVue Dx placements. IDEXX updated its 2025 guidance, raising revenue expectations to $4,095-$4,210 million and adjusting EPS outlook to $11.93-$12.43. The company launched IDEXX Cancer Dx for early detection of canine lymphoma in North American reference laboratories. Operating margin reached 31.7%, with gross margin expanding by 90 basis points to 62.4%. The company maintains its organic revenue growth projection of 6-9% for 2025.

IDEXX Laboratories (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced it will release its 2025 first quarter financial results on Thursday, May 1, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET the same day.

Investors and analysts can access the live webcast, prepared remarks transcript, and Q1 2025 Earnings Snapshot through the investor relations section of IDEXX's website. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. The conference call can also be accessed via telephone using specific dial-in numbers.

IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced its participation in two upcoming institutional investor conferences. At the BofA Securities Animal Health Summit on February 27, Mike Erickson (EVP and GM of Point of Care Diagnostics and Telemedicine) and Andrew Emerson (SVP of Corporate and CAG Finance) will engage in a fireside chat from 9:05-9:45 am EST.

Additionally, CEO Jay Mazelsky will present at the 46th Annual Raymond James Institutional Investors Conference on March 3 from 11:35 am-12:05 pm EST. Both presentations will be available via live webcasts through the company's investor relations website (www.idexx.com/investors), with archived versions accessible afterward.

IDEXX Laboratories (NASDAQ: IDXX) reported solid Q4 2024 results with revenue reaching $954 million, up 6% both reported and organic. The growth was driven by Companion Animal Group (CAG) Diagnostics recurring revenue increasing 6% reported and 7% organic.

Q4 earnings per share reached $2.62, rising 13% as reported and 10% on a comparable basis. The company's 2025 outlook projects revenue between $4,055-$4,170 million, representing 4-7% reported growth and 6-9% organic growth. EPS guidance for 2025 is set at $11.74-$12.24, indicating 10-15% reported growth.

The company plans approximately $1.5 billion in share repurchases for 2025, equivalent to ~4% of current market cap. Notable product launches include the IDEXX inVue Dx™ Cellular Analyzer and upcoming IDEXX Cancer Dx™ screening for canine lymphoma, scheduled for March 2025 release in the U.S. and Canada.